Table of Content

RESEARCH METHODOLOGY


1. Introduction to MEK Inhibitors


2. MEK Inhibitors - Mechanism of Action


3. Global MEK Inhibitors Market Overview
3.1 Current Market Scenario
3.2 Key Drugs Candidates in Research & Development
3.3 Future Market Opportunity


4. Global MEK Inhibitors Market Trends by Region
4.1 US
4.2 Europe
4.3 China
4.4 Japan


5. Global MEK Inhibitors Clinical Trials Insight
5.1 By Phase
5.2 By Status
5.3 By Region


6. Mekinist (Trametinib) – Clinical & Sales Insight
6.1 Overview
6.2 Patents & Assignees
6.3 Dosage & Price Analysis
6.4 Sales Analysis


7. Cotellic (Cobimetinib) – Clinical & Sales Insight
7.1 Overview
7.2 Patents & Assignees
7.3 Dosage & Price Analysis
7.4 Sales Analysis


8. Mektovi (Binimetinib) – Clinical & Sales Insight
8.1 Overview
8.2 Patents & Assignees
8.3 Dosage & Price Analysis
8.4 Sales Analysis


9. Koselugo (Selumitinib) – Clinical & Sales Insight
9.1 Overview
9.2 Patents & Assignees
9.3 Dosage & Price Analysis
9.4 Sales Analysis


10. MEK Inhibitors Sales Forecast 2026
10.1 Mekinist Sales Forecast
10.2 Cotellic Sales Forecast
10.3 Mektovi Sales Forecast
10.4 Koselugo Sales Analysis


11. MEK Inhibitors Market Opportunity by Indication
11.1 Melanoma
11.2 Lung Cancer
11.3 Colorectal Cancer
11.4 Thyroid Cancer
11.5 Breast Cancer


12. Global MEK inhibitors Clinical Trials Insight – Active Trials
12.1 Research
12.2 Preclinical
12.3 Phase-I
12.4 Phase-I/II
12.5 Phase-II
12.6 Phase-II/III
12.7 Registered


13. Marketed MEK Inhibitors Drugs Clinical Insight


14. Global MEK Inhibitors Market Future Perspective


15. Global MEK Inhibitors Market Dynamics
15.1 Favorable Market Parameters
15.2 Market Challenges


16. Competitive Landscape
16.1 AstraZeneca
16.2 Bristol Myers Squibb
16.3 CStone Therapeutics
16.4 GlaxoSmithKline
16.5 Immuneering
16.6 Merck
16.7 NFlection Therapeutics
16.8 Novartis
16.9 Ono Pharmaceutical
16.10 Pfizer
16.11 Roche
16.12 SpringWorks Therapeutics